BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28446055)

  • 21. Novel therapy for nasopharyngeal carcinoma--where are we.
    Tsang J; Lee VH; Kwong DL
    Oral Oncol; 2014 Sep; 50(9):798-801. PubMed ID: 24462373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
    Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
    Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STAT3 as a therapeutic target for Epstein-Barr virus (EBV): associated nasopharyngeal carcinoma.
    Ho Y; Tsao SW; Zeng M; Lui VW
    Cancer Lett; 2013 Apr; 330(2):141-9. PubMed ID: 23220625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spatiotemporal homogeneity and distinctness of the T-cell receptor β-chain repertoires in Epstein-Barr virus-associated primary and metastatic nasopharyngeal carcinomas.
    Chung YL; Wu ML
    Int J Cancer; 2018 Aug; 143(3):610-620. PubMed ID: 29468660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated analysis of the differential cellular and EBV miRNA expression profiles in microdissected nasopharyngeal carcinoma and non-cancerous nasopharyngeal tissues.
    Wan XX; Yi H; Qu JQ; He QY; Xiao ZQ
    Oncol Rep; 2015 Nov; 34(5):2585-601. PubMed ID: 26330189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic susceptibility to the endemic form of NPC.
    Bei JX; Zuo XY; Liu WS; Guo YM; Zeng YX
    Chin Clin Oncol; 2016 Apr; 5(2):15. PubMed ID: 27121875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load.
    Xu T; Su B; Huang P; Wei W; Deng Y; Sehgal V; Wang D; Jiang J; Zhang G; Li A; Yang H; Claret FX
    Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 27883284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: the relation to STAT3 activation and EGFR expression.
    Ma N; Kawanishi M; Hiraku Y; Murata M; Huang GW; Huang Y; Luo DZ; Mo WG; Fukui Y; Kawanishi S
    Int J Cancer; 2008 Jun; 122(11):2517-25. PubMed ID: 18307254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.
    Perri F; Della Vittoria Scarpati G; Giuliano M; D'Aniello C; Gnoni A; Cavaliere C; Licchetta A; Pisconti S
    Anticancer Drugs; 2015 Nov; 26(10):1017-25. PubMed ID: 26241803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: A critical review.
    Lee KT; Tan JK; Lam AK; Gan SY
    Crit Rev Oncol Hematol; 2016 Jul; 103():1-9. PubMed ID: 27179594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigational drugs for the treatment of cervical cancer.
    Barra F; Lorusso D; Leone Roberti Maggiore U; Ditto A; Bogani G; Raspagliesi F; Ferrero S
    Expert Opin Investig Drugs; 2017 Apr; 26(4):389-402. PubMed ID: 28274154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes.
    Zhang L; MacIsaac KD; Zhou T; Huang PY; Xin C; Dobson JR; Yu K; Chiang DY; Fan Y; Pelletier M; Wang Y; Jaeger S; Krishnamurthy Radhakrishnan V; JeBailey L; Skewes-Cox P; Zhang J; Fang W; Huang Y; Zhao H; Zhao Y; Li E; Peng B; Huang A; Dranoff G; Hammerman PS; Engelman J; Bitter H; Zeng YX; Yao Y
    Mol Cancer Res; 2017 Dec; 15(12):1722-1732. PubMed ID: 28851814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigational drugs for head and neck cancer.
    Bossi P; Alfieri S
    Expert Opin Investig Drugs; 2016 Jul; 25(7):797-810. PubMed ID: 27054910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination and genome-wide analysis of Epstein-Barr virus (EBV) sequences in EBV-associated gastric carcinoma from Guangdong, an endemic area of nasopharyngeal carcinoma.
    Chen JN; Zhou L; Qiu XM; Yang RH; Liang J; Pan YH; Li HF; Peng GR; Shao CK
    J Med Microbiol; 2018 Nov; 67(11):1614-1627. PubMed ID: 30239329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Xu T; Huang Z; Deng Y; Wang S; Su B; Wei W; Wang D; Jiang J; Li A; Zhang G; Yang H; Claret FX; Hu W
    J Clin Virol; 2015 Mar; 64():64-71. PubMed ID: 25728081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma.
    Dai W; Zheng H; Cheung AK; Tang CS; Ko JM; Wong BW; Leong MM; Sham PC; Cheung F; Kwong DL; Ngan RK; Ng WT; Yau CC; Pan J; Peng X; Tung S; Zhang Z; Ji M; Chiang AK; Lee AW; Lee VH; Lam KO; Au KH; Cheng HC; Yiu HH; Lung ML
    Proc Natl Acad Sci U S A; 2016 Mar; 113(12):3317-22. PubMed ID: 26951679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
    Shum E; Wang F; Kim S; Perez-Soler R; Cheng H
    Expert Opin Investig Drugs; 2017 Apr; 26(4):415-426. PubMed ID: 28277882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.